- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02267655
3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF
An Exploratory, 3-Part, Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Pulmonary Imaging Parameters in Subjects With World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated With Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT) (Part 1) and in Subjects With WHO Group 3 PH Associated With Idiopathic Pulmonary Fibrosis (IPF) on LTOT (Part 2 and Part 3)
Study Overview
Status
Conditions
Detailed Description
This is an exploratory, two-part, clinical study to evaluate the utility of HRCT to measure the pharmacodynamic effects of short term, pulsed administration of iNO using the combination product, inhaled nitric oxide/INOpulse in subjects with PH associated with COPD on LTOT. The utility of HRCT to characterize the effect of iNO on pulmonary imaging parameters as a function of a) short term inhaled iNO administration and b) NO cylinder concentration will be studied. In this study, pulmonary hypertension (PH) is defined as a tricuspid regurgitation velocity (TRV) ≥ 2.9 meters/second (m/s) or sPAP ≥ 38 mmHg by 2-D echocardiogram with Doppler or a mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg by right heart catheterization.
Eleven subjects will be enrolled; the first 6 subjects enrolled will be assigned to Part 1, the next 2 subjects enrolled will be assigned to Part 2. After Part 1 has been completed and the results reviewed by the Sponsor, the next 4 subjects will be enrolled in Part 2. The Next three subjects will be participating in Part 3.
In Part 1, six (6) subjects with adequate kidney function will be randomized to receive the 30 mcg/kg IBW/hr doses of iNO using a cylinder concentration of 4880 ppm (6.0 mg/L).
The 2 subjects enrolled in Part 2a will be randomly assigned to 1 of 2 sequences (2 subjects/sequence) to receive iNO utilizing NO cylinder concentration (4880 ppm) at a dose of 75 mcg/kg IBW/hr or Placebo set at a dose of 75 mcg/kg IBW/hr . The 2 patients from Part 2a will enter Part 2b. During Part 2b patients will receive iNO utilizing NO cylinder concentration (4880 ppm) at a dose of 75 mcg/kg IBW/hr (INOpulse® setting of 75 mcg/kg IBW/hr) for 4 weeks for at least 12 hours/day.
The 3 subjects enrolled in Part 3a and 3b. Part 3a is dose titration visit, Part 3 is 4 weeks of treatment at dose identified in Paret 3a at the discretion of the Investigator. Part 3a: subjects will receive three different doses of iNO utilizing NO cylinder concentration of (4880ppm) at a dose of 5, 10 and 15 mcg/kg IBW/hr.
The 3 patients from Part 3a will enter Part 3b and will be administered open label iNO for 4 weeks/at least 12 hrs/day at the dose determined by the Investigator in Part 3a.
Subjects will be replaced if they are unable to complete all treatment visits or of evaluable HRCT data cannot be obtained.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Edegem, Belgium, 2650
- Antwerp University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects must meet all of the following inclusion criteria to be enrolled and eligible to participate in the study:
- A confirmed diagnosis of COPD by the Global initiative for chronic Obstructive Lung Disease (GOLD) criteria
Pulmonary hypertension determined by one of the following within the past 12 months:
- A right heart catheterization (not obtained within ± 7 days of an exacerbation) with an mPAP ≥ 25 mmHg, or
- An echocardiogram (not obtained within ± 7 days of an exacerbation) with a TRV ≥ 2.9 m/s or sPAP ≥ 38 mmHg (Note: a subject with an acceptable mPAP ≥ 25 mmHg determined by right heart catheterization will meet this inclusion criteria even with a TRV < 2.9 m/s)
- Current or former smokers with at least 10 pack-years of tobacco cigarette smoking before study entry
- Age ≥ 40 years, ≤ 80 years
- A post-bronchodilatory FEV1/FVC < 0.7 and a FEV1 < 60% predicted (values obtained within 6 months prior to screening can be used unless obtained within ± 7 days of an exacerbation; otherwise, the test must be performed during screening)
- Receiving LTOT for ≥ 3 months and ≥ 10 hours per day as determined by history
- Females of childbearing potential must have a negative pre-treatment urine pregnancy test
- Signed informed consent prior to the initiation of any study mandated procedures or assessments
Exclusion Criteria:
Subjects who meet any of the following criteria are not eligible for enrollment:
- A diagnosis of asthma or other non-COPD respiratory disease, in the opinion of the Investigator
- Lack of patency of nares upon physical examination
Experienced during the last month an exacerbation requiring:
- start of or increase in systemic oral corticosteroid therapy and/or
- hospitalization
Left ventricular dysfunction as measured by:
- Screening echocardiographic evidence of left ventricular systolic dysfunction (left ventricular ejection fraction [LVEF] < 40%), or
Screening echocardiographic evidence of left ventricular diastolic dysfunction
> moderate (i.e., > Grade 2), or
- Any history of pulmonary capillary wedge pressure (PCWP), left atrial pressure (LAP) or left ventricular end diastolic pressure (LVEDP) > 18 mmHg as measured during cardiac catheterization within the past 6 months unless documented to have resolved by a subsequent cardiac catheterization
Renal impairment (i.e., an estimated GFRMDRD < 60 ml/min/1.73 m2) or history of renal failure using the equation (Levey et al., 2007):
estimated GFRMDRD = 175×Scr -1.154×Age-0.203 ×1.212 (if black) ×0.742 (if female)
where Scr = Standardized serum creatinine
- Known allergy to contrast media.
- Clinically significant valvular heart disease that may contribute to PH, including mild or greater aortic valvular disease (aortic stenosis or regurgitation) and/or moderate or greater mitral valve disease (mitral stenosis or regurgitation), or status post mitral valve replacement
- Use within 30 days of screening or current use of approved PH medications such as sildenafil or bosentan (use of Cialis® or Viagra® for erectile dysfunction is permitted)
- Use of investigational drugs or devices within 30 days prior to enrollment into the study
- Any underlying medical or psychiatric condition that, in the opinion of the Investigator, makes the subject an unsuitable candidate for the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: inhaled Nitric Oxide 30 mcg/kg IBW/hr
30 mcg/kg IBW/hr of inhaled Nitric Oxide Part 1
|
inhaled Nitric Oxide in 30 mcg/kg IBW/hr doses Part 1
Other Names:
|
Active Comparator: inhaled nitric oxide 75 mcg/kg IBW/hr
Part 2: 75mcg/Kg IBW/hr
|
inhaled nitric oxide 75 mcg/kg IBW/hr -Part 2b
Other Names:
|
Active Comparator: inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr
Part 3a: Dose tritration 5, 10 and 15 mcg/Kg IBW/hr Part 3b: continuing on dose determined by PI in 3a for 4 weeks
|
inhaled inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr dose titration
Other Names:
|
Placebo Comparator: Placebo
Placebo for 75 mcg/kg IBW/hr
|
inhaled nitric oxide 75 mcg/kg IBW/hr -Part 2b
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in lobar blood volume at total lung capacity (TLC) after dosing with pulsed iNO as measured by HRCT
Time Frame: up to 4 weeks
|
Part 1: baseline to end of treatment (1 day) Part 2: baseline to end of treatment (treatment visit B will occur at least 5 days and not more than 30 days after treatment visit A) |
up to 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in baseline measured by HRCT after dosing with pulsed iNO in Blood vessel % and density on lobar level
Time Frame: up to 4 weeks
|
Changes in baseline measured by HRCT after dosing with pulsed iNO in Blood vessel % and density on lobar level
|
up to 4 weeks
|
Changes in baseline measured by HRCT after dosing with pulsed iNO in Total lung volume at TLC
Time Frame: up to 4 weeks
|
Changes in baseline measured by HRCT after dosing with pulsed iNO in Total lung volume at TLC
|
up to 4 weeks
|
Changes in baseline measured by HRCT after dosing with pulsed iNO in Lobar volumes at TLC
Time Frame: up to 4 weeks
|
Changes in baseline measured by HRCT after dosing with pulsed iNO in Lobar volumes at TLC
|
up to 4 weeks
|
Changes in baseline measured by HRCT after dosing with pulsed iNO in Internal airflow distribution based on lobar expansion
Time Frame: up to 4 weeks
|
Changes in baseline measured by HRCT after dosing with pulsed iNO in Internal airflow distribution based on lobar expansion
|
up to 4 weeks
|
Changes in baseline measured by HRCT after dosing with pulsed iNO in Airway volume down to generation 8-10 at TLC
Time Frame: up to 4 weeks
|
Changes in baseline measured by HRCT after dosing with pulsed iNO in Airway volume down to generation 8-10 at TLC
|
up to 4 weeks
|
Changes in baseline measured by HRCT after dosing with pulsed iNO in Computational Fluid Dynamics (CFD)-based resistance on lobar level
Time Frame: up to 4 weeks
|
Changes in baseline measured by HRCT after dosing with pulsed iNO in Computational Fluid Dynamics (CFD)-based resistance on lobar level
|
up to 4 weeks
|
Changes in baseline measured by HRCT after dosing with pulsed iNO in Ventilation/perfusion (V/Q) matching
Time Frame: up to 4 weeks
|
Changes in baseline measured by HRCT after dosing with pulsed iNO in Ventilation/perfusion (V/Q) matching
|
up to 4 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Ashika Ahmed, Bellerophon Therapeutics
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Fibrosis
- Hypertension
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Pulmonary Fibrosis
- Idiopathic Pulmonary Fibrosis
- Hypertension, Pulmonary
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Protective Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Antioxidants
- Free Radical Scavengers
- Endothelium-Dependent Relaxing Factors
- Gasotransmitters
- Nitric Oxide
Other Study ID Numbers
- IK-7002-COPD-006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on inhaled Nitric Oxide - 30 mcg/kg IBW/hr
-
Bellerophon Pulse TechnologiesWorldwide Clinical TrialsTerminatedPulmonary Arterial HypertensionUnited States, Australia, Canada, Israel, Netherlands, Serbia, Spain, United Kingdom, Croatia, Portugal, Germany, Austria, Belgium, Colombia, Czechia, France, Italy, Ukraine
-
Bellerophon Pulse TechnologiesCompletedPulmonary Arterial Hypertension | Pulmonary HypertensionUnited States, Canada
-
BellerophonTerminatedChronic Obstructive Pulmonary Disease | Pulmonary Hypertension | COPDBelgium
-
The Emmes Company, LLCDuke University; Stanford UniversityCompleted